Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Chief Financial Officer | January 16, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GALECTIN THERAPEUTICS INC
Report date January 16, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.04 · Expires 2036-01-16 | Direct | 65,000 |
Reported balance
After 2026-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-16 · Grant · Acquired 65,000 · Balance 65,000 F1: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 100,000 |
Reported balance
After 2026-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-16 · Grant · Acquired 100,000 · Balance 100,000 F1: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F4: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.
F3: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.
F4: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2026 Filed Jan 21, 2026 21:47 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantRestricted Stock Unit · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-26-000030 · form4.xml · derivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis. F3 · derivative.exercise_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. F3 · derivative.expiration_date: Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:47 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001133416-26-000030 · form4.xml · derivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-01-16 F1 · security: Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027. Read SEC document |
| January 06, 2026 Filed Jan 6, 2026 21:54 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 20,354 | $3.67 | $74,695.11 |
DisclosureSEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 4 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F6 · price: The shares were sold in multiple transactions at prices ranging from $3.47 to $3.81. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 21:54 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 25,732 | $3.90 | $100,298.19 |
DisclosureSEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,968 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F5 · price: The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:54 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 13,914 | $4.20 | $58,394.28 |
DisclosureSEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,700 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F1 · shares: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:54 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001133416-26-000006 · form4.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Jan 6, 2026 21:54 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionRestricted Stock Unit · Derivative | 60,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001133416-26-000006 · form4.xml · derivative · entry 5 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units. F4 · shares: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026. F4 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026. F4 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock (right to buy) · Derivative | 18,190 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · derivative · entry 15 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 18,190 shares Expires 2034-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 28,120 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · derivative · entry 14 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 28,120 shares Expires 2032-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F2 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 18,210 | $6.22 | $113,320.83 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 10 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F6 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.30. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 18,210 | $1.11 | $20,213.10 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 9 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 28,100 | $6.22 | $174,866.30 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 8 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F6 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.30. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 18, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 28,100 | $1.98 | $55,638.00 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 7 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 2,323 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · derivative · entry 13 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,750 Underlying: Common stock · 2,323 shares Expires 2035-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F4 · derivative.exercise_date: The options vests as follows: 25% on June 30, 2025, with 25% scheduled to vest on each of December 31, 2025, June 30, 2026, on December 31, 2026. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 19,701 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · derivative · entry 12 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,190 Underlying: Common stock · 19,701 shares Expires 2034-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 9,586 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · derivative · entry 11 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,120 Underlying: Common stock · 9,586 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F2 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 2,323 | $6.03 | $14,011.64 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 6 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 2,323 | $1.23 | $2,857.29 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 5 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 19,701 | $6.03 | $118,830.52 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 4 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 19,701 | $1.11 | $21,868.11 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 9,586 | $6.03 | $57,819.88 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 9,586 | $1.98 | $18,980.28 |
DisclosureSEC source: 0001133416-25-000057 · form4.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 1,736 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001133416-25-000050 · form4.xml · derivative · entry 9 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,073 Underlying: Common stock · 1,736 shares Expires 2035-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F4 · derivative.exercise_date: The options vests as follows: 25% on June 30, 2025, with 25% scheduled to vest on each of December 31, 2025, June 30, 2026, on December 31, 2026. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 1,675 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-25-000050 · form4.xml · derivative · entry 8 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,891 Underlying: Common stock · 1,675 shares Expires 2034-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 1,880 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-25-000050 · form4.xml · derivative · entry 7 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,706 Underlying: Common stock · 1,880 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F2 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 1,736 | $6.03 | $10,467.73 |
DisclosureSEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 6 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 1,736 | $1.23 | $2,135.28 |
DisclosureSEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 5 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 1,675 | $6.03 | $10,094.56 |
DisclosureSEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 4 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 1,675 | $1.11 | $1,859.25 |
DisclosureSEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 1,880 | $6.02 | $11,321.36 |
DisclosureSEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F5 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:01 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 1,880 | $1.98 | $3,722.40 |
DisclosureSEC source: 0001133416-25-000050 · form4.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 200 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001133416-25-000047 · form4.xml · derivative · entry 9 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,809 Underlying: Common stock · 200 shares Expires 2034-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F4 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 200 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-25-000047 · form4.xml · derivative · entry 8 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,566 Underlying: Common stock · 200 shares Expires 2034-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 200 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-25-000047 · form4.xml · derivative · entry 7 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,586 Underlying: Common stock · 200 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F2 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 200 | $6.00 | $1,200.00 |
DisclosureSEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 6 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 200 | $1.72 | $344.00 |
DisclosureSEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 5 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 200 | $6.00 | $1,200.00 |
DisclosureSEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 4 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 200 | $1.11 | $222.00 |
DisclosureSEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 3 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 200 | $6.00 | $1,200.00 |
DisclosureSEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 2 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:07 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 200 | $1.98 | $396.00 |
DisclosureSEC source: 0001133416-25-000047 · form4.xml · nonDerivative · entry 1 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 10,741 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · derivative · entry 18 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,009 Underlying: Common stock · 10,741 shares Expires 2034-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F5 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 8,974 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · derivative · entry 17 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,766 Underlying: Common stock · 8,974 shares Expires 2034-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F4 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 8,914 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · derivative · entry 16 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,786 Underlying: Common stock · 8,914 shares Expires 2032-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F3 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 10,741 | $6.07 | $65,197.87 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 12 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F6 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 10,741 | $1.72 | $18,474.52 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 11 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 8,974 | $6.07 | $54,472.18 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 10 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F6 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 8,974 | $1.11 | $9,961.14 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 9 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,588 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon stock | 8,914 | $6.07 | $54,107.98 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 8 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,614 F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F6 · price: The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionCommon stock | 8,914 | $1.98 | $17,649.72 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · nonDerivative · entry 7 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | Exercise / conversionStock option (right to buy) · Derivative | 1,250 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001133416-25-000043 · form4.xml · derivative · entry 15 CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,750 Underlying: Comm stock · 1,250 shares Expires 2034-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025. F5 · derivative.exercise_date: The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.